Enfortumab vedotin, a drug used for treating urothelial cancer, effectively targets and binds to NECTIN4, a gene highly expressed in various carcinomas, delivering a cytotoxic payload directly to cancer cells. The therapeutic response to enfortumab vedotin is significantly influenced by the level of NECTIN4 expression in tumors, emphasizing the importance of understanding individual variations in gene expression for optimizing treatment efficacy.
